CHANGES IN THE SERUM LEVELS OF ESTRADIOL AND IN THE EXPRESSION OF ESTROGEN RECEPTOR ALPHA IN AN EXPERIMENTAL MODEL OF OSTEOPOROSIS

Armine V. GRIGORYAN1, Alexander B. BLAZHEV2, Tatyana M. BETOVA3, Aneliya A. DIMITROVA2

1 Department of Physiology and Pathophysiology, Medical University – Pleven, Bulgaria
2 Department of Anatomy, Histology, Cytology and Biology, Medical University – Pleven, Bulgaria
3 Department of Pathoanatomy, Medical University – Pleven, Bulgaria

Received 19 Nov 2021, Accepted 23 Dec 2022
https://doi.org/10.31688/ABMU.2022.57.1.03

Address for correspondence: Armine V. GRIGORYAN
Department of Pathophysiology, Medical University – Pleven, Bulgaria
Address: 1 Kliment Ohridski Str., 5800 Pleven, Bulgaria
E-mail: armine_ph@abv.bg

ABSTRACT

Introduction. The decrease in serum estrogens concentration at menopause disrupts the metabolic balance and leads to visceral obesity, which causes an increase in serum estradiol levels, through aromatase activity. Also, estrogen deficiency is a reason for the development of osteoporosis.

The objective of the study was to investigate the serum estradiol levels and changes in bone alpha estrogen receptor expression in an experimental model of osteoporosis.

Materials and methods. The study included 20 female Wistar rats at a reproductive age of two months, divided into two groups: group 1 (G1) – 10 ovariectomized rats, and group 2 (G2) –10 rats sham-operated. SPSS 20 software (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis of the results. For the immunohistochemical study, the nonparametric test – Mann Whitney was used, by comparing the median values. Data were presented as mean ± standard deviation, with p < 0.05 as the limit for statistical significance.

RéSUMÉ

 Modifications des niveaux sériques d’estradiol et de l’expression du récepteur alpha des oestrogènes dans un modèle expérimental d’ostéoporose

Introduction. La diminution de la concentration sérique en oestrogènes à la ménopause perturbe l’équilibre métabolique, conduisant à l’obésité viscérale, qui provoque une augmentation des taux sériques d’oestradiol, par l’activité de l’aromatase. La carence en oestro-gènes est également une cause du développement de l’ostéoporose.

L’objectif de l’étude a été d’étudier les taux sériques d’oestradiol et les changements dans l’expression des récepteurs osseux des oestrogènes alpha dans un modèle expérimental d’ostéoporose.

Matériaux et méthodes. Nous avons utilisé 20 rats Wistar, femelles, en âge de procréer, de deux mois, répartis en deux groupes : groupe 1 (G1) –10 animaux ovariectomisés et groupe 2 (G2) –10 animaux simulés. Toutes les analyses statistiques ont été effectuées à l’aide du logiciel SPSS 20 (SPSS, Inc., Chicago, IL, USA). Pour l’étude immunohistochimique, nous
INTRODUCTION

Menopause is a physiological process that leads to changes in reproductive and non-reproductive organs. The endocrine changes that occur affect various systems and organs, such as cardiovascular, endocrine, bones and others. The decrease in serum estrogens concentration disrupts the metabolic balance and changes the lipid profile, which often leads to visceral obesity. Obesity is an abnormal or excessive fat accumulation that may impair health. Obesity and metabolic syndrome are found in the menopausal period three times more often than before menopause. In the postmenopausal period, with a deficiency of estrogens, androgens from adrenal glands and fat tissue produce circulating estrogens due to aromatase enzyme. The enzyme catalyzes the conversion of androstenedione to estrone, with its further intracellular conversion to 17β-estradiol (E2). Aromatase is expressed in white adipose tissue in both women and men, and its production increases with age. Estrogen production via aromatase activity occurs in the stromal cells of the adipose tissue rather than in adipocytes, as previously considered. Aromatase-derived estrogens do not appear to be associated with a protective status of insulin sensitivity and cardiovascular disease, and the issue of osteoporosis prevention remains debatable. After menopause, the bone tissue is often irreversibly altered by osteopenia and osteoporosis, sometimes without symptoms. Osteopenia is the precursor of osteoporosis. Osteoporosis is a chronic condition that reflects reduced bone strength associated with an increased risk of fracture. Menopausal obesity combined with increased E2 synthesis is a compensatory mechanism against the development of osteoporosis, because E2 exerts its influence by binding to its receptors (ERα and ERβ) in bone tissue. Both ERα and ERβ bind E2 with high affinity in bone. The tissue sensitivity to estrogens depends on the number of estrogen receptors in the tissue.

THE OBJECTIVE OF THE STUDY was to investigate the serum estradiol levels and changes in the immunohistochemical expression of estrogen receptor alpha in bone tissue, in an experimental model of osteoporosis.

MATERIALS AND METHODS

The experimental study was approved by the Scientific Ethics Committee of Medical...
observed in the proximal femur the estrogen deficiency leading to osteoporosis is best chemical (IHC) study. According to Fonseca et al., execution of histomorphological and immunohisto-

All rats grew in standard rules of work with laboratory animals adopted from Medical University-Pleven, Bulgaria. The animals were prepared for the experiment by acclimating to the conditions for one week prior to the experiment. They were accommodated in an air-conditioned room (relative humidity 45-65%) over a 12-hour light/dark cycle, at 22±2°C, with free access to food and water.

The model of osteoporosis was created according to the method of Kharode et al. For operational purposes, a cocktail of xylazine (10 mg/kg) and ketamine (90 mg/kg) was administered intraperitoneally. We calculated for each animal a dose of anesthesia according to its weight, which is detailed in the experimental protocol. After the period of 60-days necessary for the development of osteoporosis, the animals were again anesthetized, and blood was collected by abdominal aorta puncture. The blood was collected in vacutainers, the serum was separated by centrifugation and then stored at –80 °C for examination by the enzyme-linked immunosorbent assay (ELISA) method of enzyme activity. The serum level of 17β-estradiol was determined using the ELISA immunological method. Antibodies for 17β-estradiol were purchased from R&D Systems, with catalog number KGEO014. Following animals’ euthanasia, the left femur was dissected for the preparation and staining. For IHC studies of the estrogen receptors is an important factor in assessing tissue sensitivity to estrogen1,18. E2 exerts its influence by binding to the receptors ERα and ERβ19,20. Several reports describe a beneficial effect of obesity accompanied by high serum concentrations of E2 on bone tissue21,22, because by IHC analysis ERs were found in osteoblasts, osteoclasts, and osteocytes23. In our experiment, all ovx rats were found to be overweight and had high estradiol concentrations compared to healthy controls, confirming the activation of aromatase activity after ovx. The results regarding the expression of ERs receptors in bone tissue in case of estrogens deficiency are also ambiguous. Some authors claim that the expression of ERs is reduced by estrogen deficiency24, and it changes during osteoporotic fracture25. Other authors report that the

RESULTS

Results of weight determination
The results of the study showed that, at the beginning of the experiment, there was no significant difference of animals’ weights between the two groups. At the end of the two-month period, the animals of the group G1 (336.3±41.72 g) had significantly increased their weight compared to the group G2 (270.3 5±18.27 g), (*p <0.05) (Figure 1).

Results of the determination of serum E2 concentrations
The concentrations of E2 in G1 (129.12±18.6 pg/mL) were significantly increased compared to G2 (77.05±28.2 pg/mL), with a significant difference between the two groups (* p<0.05) (Figure 2).

Histology results
The successful development of the osteoporosis model was confirmed by histological studies, stained with HE (Figure 3).

Results of immunohistochemistry
The results showed that IHC staining for ERα was primarily nuclear. It was not found a statistically significant difference in the IHC staining of ERα between the group with osteoporosis (G1) and the control group (G2) (Figure 4).

DISCUSSION
The results of our study contradict that obesity is protective against fracture and suggest that obesity is a risk factor for fractures. During menopause, adipose tissue is an important extragonadal site of E2 biosynthesis10. However, not only the presence, but also the sensitivity of the bone tissue to the circulating E2 is important. Tissue quantification of estrogen receptors is an important factor in assessing tissue sensitivity to estrogen1,18. E2 exerts its influence by binding to the receptors ERα and ERβ19,20. Several reports describe a beneficial effect of obesity accompanied by high serum concentrations of E2 on bone tissue21,22, because by IHC analysis ERs were found in osteoblasts, osteoclasts, and osteocytes23. In our experiment, all ovx rats were found to be overweight and had high estradiol concentrations compared to healthy controls, confirming the activation of aromatase activity after ovx. The results regarding the expression of ERs receptors in bone tissue in case of estrogens deficiency are also ambiguous. Some authors claim that the expression of ERs is reduced by estrogen deficiency24, and it changes during osteoporotic fracture25. Other authors report that the
Figure 1. The animal weight at the end of the experiment, with statistically significant differences in the weights in G1 and G2. Data are presented as median, minimum and maximum value and standard deviation (*p < 0.05).

Figure 2. Serum E2 concentration. Significant difference in E2 between groups G1 and G2. Data are presented as median, minimum and maximum values and standard deviation, in pg/mL, n = 20.
expression of receptors increases after estrogens deficiency, which is associated with changes in osteoblastic function, namely increased alkaline phosphatase activity\(^2\). Our studies confirmed the existence of the ERs in osteoblastic cells. We have reported high levels of alkaline phosphatase after ovx\(^2\), but nevertheless we did not find statistically significant changes in estrogen receptor expression between ovx and SHAM group. Like the study of Ikegami et al.\(^2\), we confirm that E2 does not alter ERs expression. Various research teams claim that estradiol prevents osteoporosis\(^2\)-\(^\text{31}\). However, we found that overweight animals with high estradiol concentrations had significant osteoporotic changes in the femur. The explanation probably consists in the fact that the adipose tissue is a source of pro-inflammatory cytokines\(^\text{32}\)-\(^\text{33}\), which promote osteoclast activity and bone resorption through modifying the receptor activator of nuclear factor kappa-ligand (RANKL)/RANK/osteoprotegerin (OPG) system\(^\text{32}\)-\(^\text{34}\). The unchanged expression of ERs and overproduction of inflammatory mediators induced by obesity and endocrine imbalance explain the increased bone resorption leading to osteoporosis\(^\text{35}\)-\(^\text{37}\) despite high estradiol levels. In addition, adipocytes and osteoblasts originate from a common progenitor (pluripotent mesenchymal stem cell) that has an equal tendency to differentiate into adipocytes or osteoblasts, such as alteration of the Wnt/β-catenin pathway\(^\text{38}\). This process is stimulated by transcription factors, proinflammatory cytokines and bioactive compounds, called adipokines, produced by adipose tissue especially in the presence of fatty degeneration (FD).

**Figure 3.** Preparations of femoral bone stained with HE. Magnification x 100. In animals with osteoporosis (ovx), there was thinning of the bone trabecula (T) and disruption of the relationship between them, reduction of bone mass and increase in osteoclastic activity, reduced amount of bone marrow (BM) and the presence of fatty degeneration (FD).

**Figure 4.** IHC response of ERα in femur preparations. An animal from group G1: weakly nuclear immunostaining for ERα in osteoblasts. An animal from group G2: weakly nuclear immunostaining for ERα in single osteoblasts. Light brown staining, magnification x 400. T-trabeculae, BM-bone marrow, Ob-osteoblast.
of estrogen deficiency. The link between estrogen deficiency and disorders in the catenin-dependent pathway leading to fatty degeneration of the bone marrow has already been described. Accordingly, obesity leads to fatty degeneration of the bone marrow, with an increased risk of fractures. Therefore, unchanged expression of ERs and overproduction of inflammatory mediators induced by obesity explain the increased bone resorption leading to osteoporosis, despite high estradiol levels.

**Conclusions**

Obesity has a detrimental effect on bone health, in both animals and humans. High levels of E2 in obese rats cannot be regarded as a protective factor against osteoporosis. Ovx did not alter estrogen receptor expression despite high alkaline phosphatase and E2 levels.

**Author Contributions:**
Conceptualization, A.V.G.; methodology, T.M.B. and A. B. B.; software, A.V.G.; validation, T.M.B., A. B.B.; formal analysis, A.A.D. and A.V.G.; investigation, T.M.B. and A.B.B.; resources, T.M.B., A.B.B. and A.V.G.; data curation, A.A.D.; writing—original draft preparation, A.V.G.; writing—review and editing, T.M.B., A.B.B. and A.A.D.; visualization, A.V.G.; supervision, A.A.D.; project administration, A.V.G. All the authors have read and agreed with the final version of the article.

**Compliance with Ethics Requirements:**
The authors declare no conflict of interest regarding this article.

“...The authors declare that all the procedures and experiments of this study respect the ethical standards in the Helsinki Declaration of 1975, as revised in 2008(5), as well as the national law."

“All institutional and national guidelines for the care and use of laboratory animals were followed”

**Acknowledgements:**
Special thanks to Medical University – Plevn, Bulgaria, for funding project 7/2019.

**References**

1. Meza-Muñoz D, Fajardo M, Pérez-Luque E, Malacara J. Factors associated with estrogen receptors-α (ER-α) and β (ER-β) and progesterone receptor abundance in obese and non-obese pre- and post-menopausal women. Steroids 2006; 71(6):498-503.
2. Lizcano F, Guzmán G. Estrogen deficiency and the origin of obesity during menopause. BioMed Research International 2014;2014:757461.
3. Ma S, Xi B, Yang L, Sun J, Zhao M, Bower P. Trends in the prevalence of overweight, obesity, and abdominal obesity among Chinese adults between 1993 and 2015. International Journal of Obesity 2021;45(2):427-437.
4. Jaballah A, Soltan I, Bahia W et al. The relationship between menopause and metabolic syndrome: experimental and bioinformatics analysis. Biochemical Genetics 2021;1-24.
5. Kremen J, Dolinkova M, Krajcikova J, et al. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance. The Journal of Clinical Endocrinology & Metabolism 2006; 91(11):4620-4627.
6. Wang F, Viéma V, Soronen J, et al. 17β-Estradiol and estradiol fatty acyl esters and estrogen-converting enzyme expression in adipose tissue in obese men and women. The Journal of Clinical Endocrinology & Metabolism 2013; 98(12):4923-4931.
7. Hetemäki N, Savolainen-Peltonen H, Tikkonen MJ, et al. Estrogen metabolism in abdominal subcutaneous and visceral adipose tissue in postmenopausal women. The Journal of Clinical Endocrinology & Metabolism 2017;102 (12):4588-4595.
8. Polari L, Järtnén E, Chacón MM, et al. Weight gain and inflammation regulate aromatase expression in male adipose tissue, as evidenced by reporter gene activity. Molecular and Cellular Endocrinology 2015;412:123-130.
9. Docanto MM, Yang F, Callaghan B, et al. Ghrerin and des-acyl ghrelin inhibit aromatase expression and activity in human adipose stromal cells: suppression of cAMP as a possible mechanism. Breast Cancer Research and Treatment 2014;147(1):193-201.
10. Nelson L, Bulun S. Estrone production and action. Journal of the American Academy of Dermatology 2001;45(3):S16-S124.
11. Sapir-Koren R, Livshits G. Postmenopausal osteoporosis in rheumatoid arthritis: the estrogen deficiency-immune mechanisms link. Bone 2017;103:102-115.
12. Carlson B, Saltmann S, Shirahata T, et al. Prevalence of osteoporosis and osteopenia diagnosed using quantitative CT in 296 consecutive lumbar fusion patients. Neurorad Focus 2020;49(2):E5.
13. Sinchak K, Wagner E. Estradiol signaling in the regulation of reproduction and energy balance. Frontiers in Neuroendocrinology 2012;33(4):342-363.
14. Bryant H, Glasebrook A, Yang N, Sato M. An estrogen receptor basis for raloxifene action in bone. The Journal of Steroid Biochemistry and Molecular Biology 1999;69(1-6):57-44.
15. Kharode Y, Sharp M, Bodine P. Utility of the ovarioctomized rat as a model for human osteoporosis in drug discovery. Osteoporosis. Humana Press 2008;111-124.
16. Fonseca H, Moreira-Gonçalves D, Vaz M, et al. Changes in proximal femur bone properties following ovarioectomy and their association with resistance to fracture. Journal of Bone and Mineral Metabolism 2012;30(3):281-292.
17. Jiménez P, Piazzue F, Sánchez M T, Ortega J, Soteras F, Lanas A. Free radicals and antioxidant systems in reflux esophagitis and Barrett’s esophagus. World Journal of Gastroenterology. 2005;11(18):2697.
18. Gebhart J, Rickard D, Barrett T, et al. Expression of estrogen receptor isoforms α and β messenger RNA in vaginal tissue of premenopausal and postmenopausal women. American Journal of Obstetrics and Gynecology 2001;185(6):1325-1331.
19. Bonneley E, Aubin J E. Estrone receptor-related receptor α: a mediator of estrogen response in bone. The Journal of Clinical Endocrinology & Metabolism 2005;90(5):3115-3121.
20. Sinchak K, Wagner EJ. Estradiol signaling in the regulation of reproduction and energy balance. Frontiers in Neuroendocrinology 2012;33(4):342-363.
21. Silva HG, Mendonça L, Conceição FL, Zahar SE, Farias MLF. Influence of obesity on bone density in postmenopausal women. *Arquivos Brasileiros de Endocrinologia e Metabologia* 2007;51(6):943-949.

22. Maimoun L, Mura T, Lepriec E, Avignon A, Mariano-Goulart D, Sultan A. Impact of obesity on bone mass throughout adult life: Influence of gender and severity of obesity. *Bone* 2016;90:23-30.

23. Khalid A, Krum S. Estrogen receptors alpha and beta in bone. *Bone* 2016;87:130-135.

24. Oman L, Armstrong V, Ong D, Zaman G, Price J. Is estrogen receptor alpha key to controlling bones' resistance to fracture? *Journal of Endocrinology* 2004;182(1):183-191.

25. Chow S, Leung K, Qin J, et al. Mechanical stimulation enhanced estrogen receptor expression and callus formation in diaphyseal long bone fracture healing in ovariectomized osteoporotic rats. *Osteoporosis International* 2016;27(10):2989-3000.

26. Sutherland M, Hui D, Rao L, Wylie J, Murray T. Immunohistochemical localization of the estrogen receptor in human osteoblastic SaOS-2 cells: association of receptor levels with alkaline phosphatase activity. *Bone* 1996;18(4):361-369.

27. Grigoryan A, Dimitrova A, Kostov K, et al. Changes of serum concentrations of alkaline phosphatase and metalloproteinase-9 in an ovariectomized Wistar rat model of osteoporosis. *Journal of Biomedical and Clinical Research* 2017;10(1):32-36.

28. Ikegami A, Inoue S, Hosoi T, et al. Immunohistochemical detection and northern blot analysis of estrogen receptor in osteoblastic cells. *Journal of Bone and Mineral Research* 1993;8(9):1103-1109.

29. Hidaka S, Okamoto Y, Nakajima K, Suekawa M, Liu SY. Preventive effects of traditional Chinese (Kampo) medicines on experimental osteoporosis induced by ovariectomy in rats. *Calcified Tissue International* 1997;61(3):239-246.

30. Field C, Ory S, Wahner H, Herrmann R, Judd H, Riggs B. Preventive effects of transdermal 17β-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. *American Journal of Obstetrics and Gynecology* 1993;168(1):114-121.

31. Abo-Aziza F, Zaki A, Amer A, Lofty R. Dihydrotestosterone and 17-estradiol enhancement of in vitro osteogenic differentiation of castrated male rat bone marrow mesenchymal stem cells (rBMSCs). *International Journal of Hematology-Oncology and Stem Cell Research* 2019;13(4):208.

32. Lee B, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* 2014;1842(3):446-462.

33. Weaver C, Hariton B. Interplay between the TH 17 and T Reg cell lineages: a (co-) evolutionary perspective. *Nature Reviews Immunology* 2009;9(12):883-889.

34. Cao J. Effects of obesity on bone metabolism. *Journal of Orthopedic Surgery and Research* 2011;6(1):1-7.

35. Weitzmann M. The role of inflammatory cytokines, the RANKL/OPG axis, and the immune-skeletal interface in physiological bone turnover and osteoporosis. *Scientifica* 2013;2013:125705.

36. Al-Daghri NM, Yakout S, Aljohani N et al. Changes in serum cytokines and vitamin D in Saudi postmenopausal women with osteoporosis. *International Journal of Clinical and Experimental Medicine* 2017;10(1):1179-1185.

37. Grigoryan A, Betova T, Dineva T, Popovska S, Trifonov R, Dimitrova A. The role of sclerostin and PGC-1 alpha in the pathogenesis of osteoporosis. *Arch Balk Med Union* 2020;55(2):284-289.

38. Greco E A, Lenzi A, Migliaccio S. The obesity of bone. *Therapeutic Advances in Endocrinology and Metabolism* 2015;6(6):273-286.